院外心脏骤停药物给药:静脉与骨内途径的系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Scopus和Cochrane数据库至2024年11月,纳入3项RCT共9293例≥18岁院外心脏骤停(OHCA)患者,比较骨内(IO)与静脉(IV)给药途径的临床效果。结果显示两组30天生存(OR 1.00,95%CI 0.76-1.34,p=0.98)、持续ROSC(OR 1.08,95%CI 0.97-1.21,p=0.18)、出院生存(OR 1.03,95%CI 0.84-1.25,p=0.80)和良好神经预后(OR 0.93,95%CI 0.77-1.13,p=0.49)均无显著差异。作者认为这些发现支持在紧急情况下灵活优先选择最实用的给药途径,尤其当IV通路延迟或困难时。
要点
- 3项RCT共9293例成人OHCA患者,IO与IV给药30天生存无显著差异(OR 1.00,95%CI 0.76-1.34,p=0.98)。
- 持续ROSC无显著差异(OR 1.08,95%CI 0.97-1.21,p=0.18)。
- 出院生存无显著差异(OR 1.03,95%CI 0.84-1.25,p=0.80)。
- 良好神经预后无显著差异(OR 0.93,95%CI 0.77-1.13,p=0.49)。
- 作者认为这些发现支持在紧急情况下灵活优先选择最实用的给药途径,尤其当IV通路延迟或困难时。
适用人群与场景
- 年龄≥18岁的院外心脏骤停(OHCA)患者,比较骨内(IO)与静脉(IV)药物给药途径。
研究设计与关键结果
- 研究类型:随机对照试验(RCT)的系统评价与Meta分析,纳入3项RCT共9293例患者。
- 检索PubMed、Scopus和Cochrane数据库至2024年11月,采用随机效应模型计算合并OR及95%CI。
- 30天生存:IO与IV无显著差异(OR 1.00,95%CI 0.76-1.34,p=0.98)。
- 持续ROSC:IO与IV无显著差异(OR 1.08,95%CI 0.97-1.21,p=0.18)。
- 出院生存:IO与IV无显著差异(OR 1.03,95%CI 0.84-1.25,p=0.80)。
- 良好神经预后:IO与IV无显著差异(OR 0.93,95%CI 0.77-1.13,p=0.49)。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)的系统评价与Meta分析。
- 局限:原文未报告局限性;作者指出需进一步研究患者层面结局和卫生经济学影响。
对床旁实践的改变
- 作者认为,IV与IO给药途径在OHCA患者的生存和神经功能方面结果相当,这些发现支持在紧急情况下灵活优先选择最实用的给药途径,尤其当IV通路延迟或困难时。
指南或共识出处
- 当前指南偏好IV通路,但当IV通路延迟时推荐IO(引自原文Introduction,未注明具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Out-of-hospital cardiac arrest (OHCA) is a leading cause of global mortality. Timely drug administration via vascular access is critical, with intravenous (IV) and intraosseous (IO) routes being the primary options. Current guidelines prefer IV access but recommend IO when IV access is delayed. This systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the clinical effectiveness of IO compared to IV access in adults with OHCA.
METHODS: A comprehensive search of PubMed, Scopus, and Cochrane databases through November 2024 identified RCTs comparing IO and IV drug administration in OHCA patients aged ≥18 years. Outcomes included 30-day survival, sustained return of spontaneous circulation (ROSC), survival to hospital discharge, and survival with favorable neurological outcomes. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using a random-effects model.
RESULTS: Three RCTs comprising 9293 patients were included. No significant differences were found between IO and IV routes for 30-day survival (OR: 1.00, 95 % CI: 0.76-1.34, p = 0.98), sustained ROSC (OR: 1.08, 95 % CI: 0.97-1.21, p = 0.18), survival to hospital discharge (OR: 1.03, 95 % CI: 0.84-1.25, p = 0.80), or favorable neurological outcomes (OR: 0.93, 95 % CI: 0.77-1.13, p = 0.49).
CONCLUSION: IV and IO access routes demonstrated comparable outcomes for survival and neurological function in OHCA. These findings support the flexibility to prioritize the most practical route in emergency settings, particularly when IV access is delayed or challenging. Further research should explore patient-level outcomes and health economic implications.
参考来源
- Saad M, Sohail MU, Waqas SA, et al. Intravenous vs intraosseous administration of drugs for out of hospital cardiac arrest: A systematic review and meta-analysis. Am J Emerg Med. 2025. PMID: 40023136. doi:10.1016/j.ajem.2025.02.029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。